Document is current
Any future updates will be listed below
-
Authors
Alessi, Sarah https://orcid.org/0000-0001-9517-4203
Maggioni, Roberta
Luzzago, Stefano
Summers, Paul E. https://orcid.org/0000-0002-5085-1095
Renne, Giuseppe
Zugni, Fabio
Belmonte, Maddalena
Raimondi, Sara
Vignati, Silvano
Mistretta, Francesco A.
Di Meglio, Letizia
D’Ascoli, Elisa
Scarabelli, Alice
Marvaso, Giulia
De Cobelli, Ottavio
Musi, Gennaro
Jereczek-Fossa, Barbara Alicja
Curigliano, Giuseppe
Petralia, Giuseppe
-
Funding
Funding for this research was provided by:
Ministero della Salute
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 4 July 2024
First Online: 16 July 2024
Declarations
:
: Author Paul Summers declares a relationship with the following companies: QMRI Tech. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. Giuseppe Curigliano and Barbara Alicja Jereczek-Fossa declare relationships with the following companies: Roche, Bayer, Janssen, Carl Zeiss, Ipsen, Accuray, Astellas, Elekta, IBA, and Astra Zeneca (all outside the current project). The Division of Radiotherapy, IEO received research grants from Accuray and IBA (all outside the current project); BMS, Pfizer, Novartis, Lilly, Astra Zeneca, Daichii Sankyo, Merck, Seagen, Ellipsis, Gilead, Menarini, and Relay.
: The Ethics Committee of the Istituto Europeo Oncologico has approved the study and waived the collection of written informed consent specific to the study as all patients had provided such consent for the performance of the mpMRI examination and surgical procedures, and for the use of their clinical and medical information for research and scientific dissemination purposes.
: Written informed consent was obtained from all patients for the use of their clinical and medical information for research and scientific dissemination purposes.
: ADC values predict biochemical recurrence risk after radical prostatectomy and may serve as a prognostic biomarker in patients with prostate cancer.
